A vaccine for this particular strain of Ebola,
Bundibugyo virus (BDBV), is in animal trials at this time, but they also are trying other treatments and combination of treatments, so there may be hope for some.
----
"The World Health Organization has declared this outbreak a
public health emergency of international concern, noting that the risk is high at national and regional levels. While the average case fatality rate for Ebola disease is typically around 50%, rates for this specific strain have ranged between
30% and 50% in recent outbreaks, with mortality potentially higher in areas lacking adequate medical care."
---
"
MBP134 is an experimental
pan-ebolavirus monoclonal antibody cocktail designed to treat Ebola virus disease by targeting multiple viral strains, including
Ebola virus (EBOV),
Sudan virus (SUDV), and
Bundibugyo virus (BDBV). Developed by
Mapp Biopharmaceutical in collaboration with the
Biomedical Advanced Research and Development Authority (BARDA), it consists of two human antibodies,
ADI-15878 and
ADI-23774, which bind to non-overlapping epitopes on the viral glycoprotein.
Unlike FDA-approved treatments such as Inmazeb and Ebanga, which only target the Zaire species of Ebola,
MBP134 offers broad protection across different ebolavirus species. In non-clinical studies, it demonstrated the ability to
protect monkeys and guinea pigs from lethal challenges, even when administered
4-7 days after infection. An optimized afucosylated version,
MBP134AF, enhances immune system recruitment to further improve efficacy.
During the
2022 Sudan ebolavirus outbreak in Uganda, the U.S. government deployed emergency doses of MBP134 under
compassionate use guidelines. While individual administration showed modest survival rates in animal models, studies indicated that combining MBP134 with the antiviral
remdesivir significantly improved survival outcomes in non-human primates infected with Sudan virus. " (LLM)
https://www.cell.com/cell-host-microbe/f...18)30631-0
Any other effective treatment was made illegal in hospitals during the Covid-19 mRNA vaccine Holocaust. 
